Treatment outcome and prognostic factors of Korean patients with chronic lymphocytic leukemia: a multicenter retrospective study

Yunsuk CHOI; Jung-Hee LEE; Chul-Won JUNG; Jae-Cheol JO; ,-Jin-Seok KIM; Inho KIM; Silvia PARK; June-won CHEONG; Sang-Hyuk PARK; Sung-Yong KIM; Hong-Ghi LEE.
The Korean Journal of Internal Medicine ; : 194-204, 2021.
Artículo en Inglés | WPRIM | ID: wpr-875447

Documentos relacionados

  1. Treatment outcome and prognostic factors of Korean patients with chronic lymphocytic leukemia: a multicenter retrospective study.
  2. [Chronic lymphocytic leukemia: current standards and novel approaches].
  3. [Efficacy of a bendamustine and rituximab combination in first-line therapy for chronic lymphocytic leukemia: Results of the BEN-001 study].
  4. Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study.
  5. Real-world outcomes upon second-line treatment in patients with chronic lymphocytic leukaemia.
  6. [Clinical features and prognosis of high hyperdiploid childhood acute lymphoblastic leukemia: a multicenter retrospective analysis in Fujian Province, China].
  7. [Prolymphocytic leukemia: the therapeutic strategy].
  8. Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.
  9. The long-term outcome of patients in the LRF CLL4 trial: the effect of salvage treatment and biological markers in those surviving 10 years.
  10. Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.